Dashboard
Manage Tickers

CCCCC4 Therapeutics, Inc.

Nasdaq c4therapeutics.com


$ 5.73 $ 0.33 (6.11 %)    

Monday, 09-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 5.73
$ 5.72 x 400
$ 5.73 x 197
-- - --
$ 1.06 - $ 11.88
2,909,114
na
397.31M
$ 2.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-01-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-11-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

methanex-merck-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Methanex, Merck And Other Big Stocks Movin...
09/09/2024 12:11:16

c4-therapeutics-shares-are-trading-lower-the-company-announced-the-abstract-sharing-clinical-data-from-its-ongoing-phase-1-clinical-trial-of-cft1946-in-mutant-braf-v600-solid-tumors-was-released-in-conjunction-with-the-esmo-congress-2024
C4 Therapeutics shares are trading lower. ...
09/09/2024 11:39:31

why-summit-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Summit Therapeutics Shares Are Trading...
09/09/2024 10:08:36

reported-sunday-c4-therapeutics-to-reveal-preliminary-cft1946-monotherapy-phase-1-clinical-data-at-esmo-congress-2024
Reported Sunday, C4 Therapeutics To Reveal...
09/09/2024 07:20:06

c4-therapeutics-announced-the-esmo-congress-decided-to-move-c4ts-previously-accepted-preliminary-monotherapy-phase-1-abstract-for-cft1946-to-an-oral-presentation
C4 Therapeutics Announced The ESMO Congres...
08/14/2024 11:16:03

bmo-capital-reiterates-outperform-on-c4-therapeutics-maintains-20-price-target
BMO Capital Reiterates Outperform on C4 Th...
08/06/2024 13:47:37

BMO Capital analyst Etzer Darout reiterates C4 Therapeutics (NASDAQ:CCCC) with a Outperform and maintains $20 price target.

c4-therapeutics-q2-2024-gaap-eps-026-beats-037-estimate-sales-1201m-beat-478m-estimate-cash-cash-equivalents-and-marketable-securities-of-2957m-as-of-june-30-expected-to-provide-runway-into-2027
C4 Therapeutics Q2 2024 GAAP EPS $(0.26) B...
08/01/2024 11:54:32

c4-therapeutics-to-present-preliminary-monotherapy-data-from-ongoing-phase-1-trial-of-cft1946-at-esmo-congress-2024
C4 Therapeutics To Present Preliminary Mon...
07/16/2024 20:01:56

c4-therapeutics-taps-ron-cooper-of-albireo-pharma-as-board-chair-succeeding-bruce-downey
C4 Therapeutics Taps Ron Cooper of Albireo...
06/10/2024 11:48:00

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...

key-takeaways-from-c4-therapeutics-analyst-ratings
Key Takeaways From C4 Therapeutics Analyst...
05/09/2024 18:01:07

wells-fargo-maintains-equal-weight-on-c4-therapeutics-raises-price-target-to-8
Wells Fargo Maintains Equal-Weight on C4 T...
05/09/2024 15:58:31

Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target fr...

stifel-maintains-buy-on-c4-therapeutics-raises-price-target-to-14
Stifel Maintains Buy on C4 Therapeutics, R...
05/09/2024 13:57:15

Stifel analyst Bradley Canino maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $13 to $14.

c4-therapeutics-cash-cash-equivalents-and-marketable-securities-total-2992m-as-of-march-31-2024-expected-to-provide-runway-into-2027
C4 Therapeutics' Cash, Cash Equivalents an...
05/08/2024 11:26:24

c4-therapeutics-q1-2024-gaap-eps-041-beats-047-estimate-sales-3039m-miss-8100m-estimate
C4 Therapeutics Q1 2024 GAAP EPS $(0.41) B...
05/08/2024 11:25:11

c4-therapeutics-presents-new-preclinical-data-for-cft1946-highlighting-superior-activity-as-a-single-agent-to-clinically-approved-braf-inhibitor-standard-of-care-combinations-at-the-american-association-for-cancer-research-annual-meeting-2024
C4 Therapeutics Presents New Preclinical D...
04/08/2024 12:25:57

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...

c4-therapeutics-to-present-new-preclinical-data-on-highly-selective-orally-bioavailable-bidac-degraders-at-the-american-association-for-cancer-research-annual-meeting-2024
C4 Therapeutics To Present New Preclinical...
03/05/2024 21:35:47

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...

c4-therapeutics-shares-are-trading-higher-after-the-company-announced-a-strategic-discovery-collaboration-with-merck-kgaa-against-critical-oncogenic-proteins-in-which-the-company-will-receive-a-16-million-upfront-payment
C4 Therapeutics shares are trading higher ...
03/04/2024 14:24:49

Core News & Articles
C4 Therapeutics Has Entered Into A License...
03/04/2024 12:05:55

breaking-down-c4-therapeutics-4-analysts-share-their-views
Breaking Down C4 Therapeutics: 4 Analysts ...
02/26/2024 16:00:42

morgan-stanley-maintains-equal-weight-on-c4-therapeutics-raises-price-target-to-8
Morgan Stanley Maintains Equal-Weight on C...
02/26/2024 15:42:36

Morgan Stanley analyst Terence Flynn maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION